NIAGARA investigator Thomas Powles at #ESMO24 (Reynald Castaneda for Endpoints News)

September 16, 2024 03:59 AM EDTUpdated 06:24 AM

AstraZeneca unveils what it calls ‘practice-changing’ Imfinzi data in bladder cancer

Reynald Castañeda

Deputy Editor

BARCELONA — In a result that’s likely to change how some bladder cancer patients get care, AstraZeneca said that its drug Imfinzi boosted patient survival alongside …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca unveils what it calls ‘practice-changing’ Imfinzi data in bladder cancer

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Sofinnova outlines $550M fund after IPOs and M&A deals

Exclusive: Florida cancer biotech raises $100M Series A

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

As­traZeneca un­veils what it calls ‘prac­tice-chang­ing’ Imfinzi da­ta in blad­der can­cer

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

AstraZeneca unveils what it calls ‘practice-changing’ Imfinzi data in bladder cancer

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Sofinnova outlines $550M fund after IPOs and M&A deals

Exclusive: Florida cancer biotech raises $100M Series A

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.